After 20 years in clinical operations across the US, EU, UK, LatAm, APAC, CEE and the former USSR, I keep seeing the same pattern: a trial’s fate is usually decided months before the first patient walks through a site door.
Recent data: in over half of studies, site selection to full activation takes 5+ months, and 39% say timelines have worsened vs. two years ago — with sponsor-CRO communication rated average/poor by 47%. Earlier research put overall trial delay rates as high as 86%.
Where it typically breaks down:
- Protocol design that’s scientifically sound but operationally unrealistic — visit burden and IMP logistics never stress-tested against real site capacity. A common issue: misalignment between local Standard of Care and the protocol’s treatment/assessment schedule. “Per SoC” gets interpreted differently across countries, and mismatches in visit cadence, comedication rules, or washouts surface late at EC review — triggering costly amendments.
- KOL and country selection driven by reputation rather than genuine feasibility fit — regulatory maturity, patient density, and real experience with the pathway.
- CTIS vs. non-CTIS realities. CTIS was built for a ~60-day Part I/II review. In practice, average EU approval still runs 110+ days, vs. 30–60 days elsewhere — driven by inconsistent Member State requirements and Part I/II gaps. Non-CTIS countries (Western Balkans, parts of CEE, CIS) follow different EC/RA logic — a “CTIS mindset” there is costly.
- Vendor contracting lagging the regulatory track instead of running parallel — labs, IRT, drug supply, imaging vendors contracted late become the hidden critical path.
- Site activation & FPI — readiness too often assumed, not verified. Sites can look approved on paper and be unprepared in practice. A related driver: weak site qualification combined with Client pressure to activate sites the CRO’s own assessment would flag as back-up-tier. Pushing a back-up site into the primary list rarely saves time — it relocates the delay into slower contracting, EC/RA turnaround, or a longer gap to FPI.
None of this is one failure — it’s interdependent gaps across protocol, site capacity, approval and contracting, compounded by sponsor-CRO misalignment. Budget gaps alone can add weeks to activation.
This is the gap Nushev Biotech Advisory works in.
We sit between sponsor strategy and CRO execution — stress-testing protocol feasibility, matching country/site/KOL selection to real fit (CTIS and non-CTIS alike), sequencing vendor contracting against the regulatory path, and auditing site readiness before it becomes an FPI surprise.
Heading into study start-up and want a second set of eyes on the plan — before the timeline slips, not after? Let’s talk.
#ClinicalTrials #ClinicalOperations #CTIS #ClinicalResearch #Biotech #StudyStartUp #CRO